Antiangiogenic agents.
A greater understanding of the complex process of tumor-induced angiogenesis, coupled with the notion that tumors require a blood supply to both grow and metastasize, has fueled the search for agents that block or disrupt the angiogenic process. Because normal vascular endothelial cells (ECs) turn over so slowly, conventional wisdom suggests that an antiangiogenic approach to cancer therapy should offer improved efficacy and reduced toxicity, without the potential for drug resistance. Numerous reports have identified small molecules or antibodies that can interfere with one or more key steps in EC signaling, migration or differentiation. Three new compounds, ZD4190, SU6668 and PD 0173073, have been reported during the past year to have significant and selective antiangiogenic activity, as well as antitumor activity.
Klohs
W D
WD
Department of Drug Development, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, MI 48105, USA.
Hamby
J M
JM
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D016228:Endothelial Growth Factors / Q000276:immunology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D005109:Extracellular Matrix / Q000473:pathology; D006801:Humans; D008222:Lymphokines / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors